{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:45:34Z","timestamp":1791816334688,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.eururo.2017.10.003","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T20:15:25Z","timestamp":1523391325000},"page":"738-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"title":["Predicting Response to Intravesical Bacillus Calmette-Gu\u00e9rin Immunotherapy: Are We There Yet? A Systematic Review"],"prefix":"10.1016","volume":"73","author":[{"given":"Ashish M.","family":"Kamat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comperat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly A.","family":"Ingersoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim P.","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2017.10.003_bib0405","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0410","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC Nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0415","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0420","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0425","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0430","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? analysis of a quarter century of literature","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0435","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0440","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0445","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15 215 patients","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0450","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0455","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0022-5347(01)65458-2","article-title":"Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy","volume":"156","author":"Hurle","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0460","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)36724-1","article-title":"Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy","volume":"148","author":"Cookson","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0465","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.10.003_bib0470","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.10.003_bib0475","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(01)69072-4","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup","volume":"167","author":"Davis","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0480","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0485","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","article-title":"Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up","volume":"54","author":"Hurle","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.10.003_bib0490","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0495","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1464-410X.2009.09137.x","article-title":"The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder","volume":"106","author":"Boorjian","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.10.003_bib0500","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0505","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance bacillus Calmette-Guerin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0510","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1309\/ADJL7E810U1H42BJ","article-title":"Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings","volume":"127","author":"Yoder","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0515","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.juro.2011.10.144","article-title":"Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial","volume":"187","author":"Kamat","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0520","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bju.13186","article-title":"Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies","volume":"117","author":"Kamat","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.10.003_bib0525","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.1996.14.10.2646","article-title":"Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome","volume":"14","author":"Lacombe","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0530","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0022-5347(01)63839-4","article-title":"p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors","volume":"159","author":"Pages","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0535","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0022-5347(01)64825-0","article-title":"Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation","volume":"157","author":"Ovesen","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0540","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0022-5347(01)61770-1","article-title":"Correlation and prognostic significance of p53, p21WAF1\/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy","volume":"161","author":"Zlotta","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0545","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1159\/000020364","article-title":"p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?","volume":"38","author":"Schmitz-Drager","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0550","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2017.10.003_bib0555","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/01.ju.0000059681.67567.12","article-title":"The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin","volume":"169","author":"Bilen","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0560","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors","volume":"155","author":"Luftenegger","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0565","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0570","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","article-title":"Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.10.003_bib0575","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.10.003_bib0580","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2006.06.006","article-title":"HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours","volume":"51","author":"Lebret","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0585","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.urology.2009.02.053","article-title":"Efficacy of bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines","volume":"74","author":"Videira","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.10.003_bib0590","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/1078-0432.CCR-06-0595","article-title":"Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer","volume":"12","author":"Kitamura","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.10.003_bib0595","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jcp.47.4.309","article-title":"Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy","volume":"47","author":"Jackson","year":"1994","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0600","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0605","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1442-2042.2006.01697.x","article-title":"Bacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells","volume":"14","author":"Naoe","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0610","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1464-410X.2004.05176.x","article-title":"Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer?","volume":"94","author":"Beatty","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.10.003_bib0615","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy","volume":"55","author":"Ayari","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0620","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2017.10.003_bib0625","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.juro.2008.11.090","article-title":"Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation","volume":"181","author":"Takayama","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0630","first-page":"1762","article-title":"Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin","volume":"47","author":"Ratliff","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.10.003_bib0635","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","article-title":"Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"Bohle","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0640","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus Calmette-Guerin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2017.10.003_bib0645","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0650","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2017.10.003_bib0655","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.juro.2007.07.118","article-title":"The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study","volume":"178","author":"Yutkin","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.06.008","article-title":"Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder","volume":"32","author":"Nunez-Nateras","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0665","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2017.10.003_bib0670","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","article-title":"Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy","volume":"99","author":"Jackson","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0675","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2017.10.003_bib0680","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","article-title":"Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity","volume":"131","author":"Nadler","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0685","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.juro.2007.07.041","article-title":"Interleukin-6\/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma","volume":"178","author":"Cai","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0690","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3892\/etm.2012.634","article-title":"Prediction of response to bacillus Calmette-Guerin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio","volume":"4","author":"Cai","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.eururo.2017.10.003_bib0695","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0700","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","article-title":"Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guerin immunotherapy","volume":"14","author":"Shintani","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0705","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine Panel for Response to Intravesical Therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0710","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.juro.2007.07.139","article-title":"Editorial comment","volume":"178","author":"Boehle","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0715","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","article-title":"Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival","volume":"23","author":"Leibovici","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0720","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population","volume":"116","author":"Lima","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.10.003_bib0725","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2010.11.031","article-title":"NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder cancer","volume":"59","author":"Chiong","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0730","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/1078-0432.CCR-04-1101","article-title":"Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer","volume":"11","author":"Gu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.10.003_bib0735","doi-asserted-by":"crossref","first-page":"75176","DOI":"10.18632\/oncotarget.12661","article-title":"Genomic characterization of high-risk non-muscle invasive bladder cancer","volume":"7","author":"Meeks","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2017.10.003_bib0740","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","article-title":"Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours","volume":"60","author":"Agundez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0745","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0750","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMc062714","article-title":"Use of statins and outcome of BCG treatment for bladder cancer","volume":"355","author":"Hoffmann","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.10.003_bib0755","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1056\/NEJMc070117","article-title":"Statins and the effect of BCG on bladder cancer","volume":"356","author":"Kamat","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.10.003_bib0760","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1172\/JCI116202","article-title":"Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells","volume":"91","author":"Kuroda","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2017.10.003_bib0765","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.juro.2009.06.026","article-title":"Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer","volume":"182","author":"Boorjian","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0770","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0775","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2017.10.003_bib0780","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.10.003_bib0785","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2017.10.003_bib0790","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0795","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2017.10.003_bib0800","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2017.10.003_bib0805","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.22503","article-title":"Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha","volume":"109","author":"Esuvaranathan","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2017.10.003_bib0810","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.urolonc.2008.08.003","article-title":"Retinoblastoma protein expression predicts response to bacillus Calmette-Guerin immunotherapy in patients with T1G3 bladder cancer","volume":"28","author":"Cormio","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0815","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.ju.0000063685.29339.24","article-title":"Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome","volume":"170","author":"Hausladen","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0820","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002400050040","article-title":"Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus Calmette-Guerin (BCG) intravesical instillation therapy for superficial bladder cancers","volume":"26","author":"Okamura","year":"1998","journal-title":"Urol Res"},{"key":"10.1016\/j.eururo.2017.10.003_bib0825","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11255-005-0919-4","article-title":"The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients","volume":"37","author":"Serdar","year":"2005","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0830","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2008.09.062","article-title":"Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin","volume":"56","author":"Palou","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0835","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/bjc.2013.571","article-title":"Response of high-risk of recurrence\/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy","volume":"109","author":"Lima","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2017.10.003_bib0840","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000049768","article-title":"Prospective evaluation of Ki-67 labeling in predicting the recurrence and progression of superficial bladder transitional cell carcinoma","volume":"40","author":"Blanchet","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0845","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.juro.2015.06.093","article-title":"FGFR3 Down-Regulation is Involved in bacillus Calmette-Guerin Induced Bladder Tumor Growth Inhibition","volume":"195","author":"Langle","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.10.003_bib0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2008.02.015","article-title":"Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer","volume":"184","author":"Ahirwar","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.eururo.2017.10.003_bib0855","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.urology.2005.04.033","article-title":"Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer","volume":"66","author":"Zhao","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.10.003_bib0860","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1007\/s11033-011-1366-1","article-title":"Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort","volume":"39","author":"Jaiswal","year":"2012","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.eururo.2017.10.003_bib0865","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1158\/1940-6207.CAPR-10-0035","article-title":"Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer","volume":"3","author":"Chen","year":"2010","journal-title":"Cancer Prev Res (Phila)"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817308503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817308503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T10:20:04Z","timestamp":1529662804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817308503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0302283817308503"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.10.003","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting Response to Intravesical Bacillus Calmette-Gu\u00e9rin Immunotherapy: Are We There Yet? A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}